Evaluation of two drugs, thioguanine and mercaptopurine, on the survival of patients with acute lymphocytic leukemia

Comparison of the prognosis of patients with acute lymphocytic leukemia treated with two drugs, thioguanine, and mercaptopurine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241202063919N1

Enrollment

130

Registered

2025-05-21

Start date

2025-04-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphocytic leukemia. Acute lymphoblastic leukemia [ALL]

Interventions

Intervention group: The group receiving tiaguanine at a dose of 40 mg/m2..

Eligibility

Sex/Gender

All

Age

1 Years to 13 Years

Inclusion criteria

Inclusion criteria: Age above 1 year and less than 13 years Patients with acute lymphocytic leukemia

Exclusion criteria

Exclusion criteria: People whose file information is incomplete

Design outcomes

Primary

Measure	Time frame
Comparison of the prognosis of patients with acute lymphocytic leukemia treated with two drugs: thioguanine and mercaptopurine. Timepoint: Study variables before the start of the study - 3 months - 6 months - 9 months and 12 months after the start of the study. Method of measurement: The method of measuring the amount of white blood cells-hemoglobin-platelets-red blood cells and the amount of liver enzymes is a blood test. Bone marrow relapse is performed by bone marrow testing and measuring M1 and M2 cells. Also, to measure CNS relapse, the number of white blood cells in the cerebrospinal fluid is examined. Age, gender, and race are completed by a questionnaire. Also, the amount of hospitalization of patients after receiving the drug in the two groups is evaluated by a questionnaire.	—

Measure

Time frame

Comparison of the prognosis of patients with acute lymphocytic leukemia treated with two drugs: thioguanine and mercaptopurine. Timepoint: Study variables before the start of the study - 3 months - 6 months - 9 months and 12 months after the start of the study. Method of measurement: The method of measuring the amount of white blood cells-hemoglobin-platelets-red blood cells and the amount of liver enzymes is a blood test. Bone marrow relapse is performed by bone marrow testing and measuring M1 and M2 cells. Also, to measure CNS relapse, the number of white blood cells in the cerebrospinal fluid is examined. Age, gender, and race are completed by a questionnaire. Also, the amount of hospitalization of patients after receiving the drug in the two groups is evaluated by a questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Dehghan Mongabadi

Islamic Azad University

hosseindemo.res@gmail.com+98 35 3824 9502

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026